SEC Form 4 · accession 0001209191-19-006405
Deciphera Pharmaceuticals, Inc. · DCPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Lee Flynn
Officer — Chief Scientific Officer
Period of report
Jan 30, 2019
Accepted (ET)
Feb 1, 2019 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001654151
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $26.35 | Jan 30, 2019 | A | 75,000 | A | — | Jan 29, 2029 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments following the vesting commencement date of January 1, 2019 , subject to continued service through such dates.